Ethinylestradiol sulfonate/norethisterone acetate
From Wikipedia, the free encyclopedia
Combination of | |
---|---|
Ethinylestradiol sulfonate | Estrogen |
Norethisterone acetate | Progestogen |
Clinical data | |
Trade names | Deposiston |
Other names | EES/NETA |
Routes of administration | By mouth |
Drug class | Estrogen; Progestogen |
Identifiers | |
CAS Number |
Ethinylestradiol sulfonate/norethisterone acetate (EES/NETA), sold under the brand name Deposiston, is a combination medication of ethinylestradiol sulfonate (EES), an estrogen, and norethisterone acetate (NETA), a progestin, which was used as a combined birth control pill for women.[1] It was formulated as oral tablets and contained 1 mg EES and 5 mg NETA per tablet.[2][3][1] The medication had a long-lasting depot effect and was taken only once per week, for a total of four tablets per cycle.[1][2] It was developed and marketed by Jenapharm and was previously available in Germany.[2][1][3] EES/NETA was introduced for medical use in 1978.[1]
See also[]
- List of combined sex-hormonal preparations § Estrogens and progestogens
References[]
- ^ a b c d e Schwarz S, Onken D, Schubert A (July 1999). "The steroid story of Jenapharm: from the late 1940s to the early 1970s". Steroids. 64 (7): 439–45. doi:10.1016/S0039-128X(99)00003-3. PMID 10443899. S2CID 40156824.
6.2. New estrogens. In 1967, Jenapharm, in conjunction with the Academy of Sciences (Kurt Ponsold, Gu¨nter Bruns, and Kurt Schubert in Jena and Hans Schick and Bernard Lu¨cke in Berlin), started a program of searching for new estrogens. [...] orally administered, strongly active estrogens with a depot effect. [...] the second objective was successfully attained. The rationale that an a-branched alkanesulfonic acid ester of ethinyl estradiol with a medium chain length should lead to a depot effect without the danger of active ingredient accumulation on longer usage [15] led in 1978 to the first once-a-week oral contraceptive (DEPOSISTONt), a combination of ethinylestradiol 3-isopropylsulfonate (17) and norethisterone acetate [16]. TURISTERONt, an estrogenic monotherapy with compound 17 that can still justify its position today [17], followed in 1980, as a therapy of prostate cancer. [...]
- ^ a b c Freimut A. Leidenberger (17 April 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 542–. ISBN 978-3-662-08110-5.
- ^ a b Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 338–. ISBN 978-3-7692-2114-5.
Estrogens and antiestrogens | |||||||||
---|---|---|---|---|---|---|---|---|---|
Estrogens |
| ||||||||
Antiestrogens |
| ||||||||
|
Progestogens and antiprogestogens | |||||
---|---|---|---|---|---|
Progestogens (and progestins) |
| ||||
Antiprogestogens |
| ||||
|
Estrogen receptor modulators | |||||||
---|---|---|---|---|---|---|---|
ER |
| ||||||
GPER |
| ||||||
|
Progesterone receptor modulators | |||||||
---|---|---|---|---|---|---|---|
PR |
| ||||||
mPR (PAQR) |
| ||||||
|
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by . |
- v
- t
Retrieved from ""
Categories:
- Abandoned drugs
- Combined estrogen–progestogen formulations
- Genito-urinary system drug stubs
Hidden categories:
- Infobox drug articles with non-default infobox title
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- All stub articles